extract: 2025-03-01-medicare-prior-authorization-glp1-near-universal

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -29,6 +29,12 @@ Real-world persistence data from 125,474 commercially insured patients shows the
 
 The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+
+MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
+
 ---
 
 Relevant Notes:

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -29,6 +29,12 @@ PACE represents the extreme end of value-based care alignment—100% capitation
 
 GLP-1 persistence data illustrates why value-based care requires risk alignment: with only 32.3% of non-diabetic obesity patients remaining on GLP-1s at one year (15% at two years), the downstream savings that justify the upfront drug cost never materialize for 85% of patients. Under fee-for-service, the pharmacy benefit pays the cost but doesn't capture the avoided hospitalizations. Under partial risk (upside-only), providers have no incentive to invest in adherence support because they don't bear the cost of discontinuation. Only under full risk (capitation) does the entity paying for the drug also capture the downstream savings—but only if adherence is sustained. This makes GLP-1 economics a test case for whether value-based care can solve the "who pays vs. who benefits" misalignment.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+
+Medicare Advantage plans bearing full capitated risk increased GLP-1 prior authorization from <5% to nearly 100% within two years (2023-2025), demonstrating that even full-risk capitation does not automatically align incentives toward prevention when short-term cost pressures dominate. Both BCBS and UnitedHealthcare implemented universal PA despite theoretical alignment under capitation.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-03-01-medicare-prior-authorization-glp1-near-universal.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "medicare-advantage-prior-authorization-escalation-from-5-to-100-percent-demonstrates-capitated-plans-prioritize-short-term-cost-avoidance-over-long-term-prevention.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "medicare-advantage-prior-authorization-escalation-from-5-to-100-percent-demonstrates-capitated-plans-prioritize-short-term-cost-avoidance-over-long-term-prevention.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "medicare-advantage-prior-authorization-escalation-from-5-to-100-percent-demonstrates-capitated-plans-prioritize-short-term-cost-avoidance-over-long-term-prevention.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/2025-03-01-medicare-prior-authorization-glp1-near-universal.md

@@ -7,9 +7,13 @@ date: 2025-03-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, prior-authorization, medicare-advantage, formulary, access-barriers]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -44,3 +48,12 @@ Analysis of GLP-1 coverage and prior authorization requirements under Medicare A
 PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 WHY ARCHIVED: Near-universal PA for GLP-1s under MA demonstrates that capitation alone doesn't align incentives for prevention — MA plans still manage to short-term cost metrics
 EXTRACTION HINT: Focus on the tension between theoretical capitation incentives (cover prevention → save money) and actual MA behavior (restrict access → minimize short-term spend)
+
+
+## Key Facts
+- Injectable semaglutide (Ozempic) covered by 98.0% of MA plans in 2025
+- Tirzepatide (Mounjaro) covered by 96.2% of MA plans in 2025
+- Oral semaglutide covered by 84.8% of MA plans in 2025
+- Dulaglutide covered by 87.5% of MA plans in 2025
+- Only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026
+- GLP-1s for weight loss/obesity remain excluded under Medicare Part D until BALANCE model demonstration begins July 2026